BICO has acquired Advanced BioMatrix, an innovative company focused on 3D applications, to, together, ensure a market leading portfolio of bioinks and reagents
BICO has acquired Advanced BioMatrix, an innovative company focused on 3D applications, to, together, ensure a market leading portfolio of bioinks and reagents
STOCKHOLM, Aug. 27, 2021 /PRNewswire/ -- BICO, the leading Bio Convergence company, has acquired all outstanding shares in Advanced BioMatrix Corp. (Advanced BioMatrix), an American company focusing on 3D research applications. The Advanced BioMatrix portfolio includes collagen bioinks, high purity extracellular matrix proteins, chemically modified proteins and polysaccharides, and other reagents and cell assays, sold to research institutions, and pharmaceutical and biotech companies. The company has a particularly strong position in reagents and in producing high-quality collagen and collagen inks intended for 3D bioprinting.
斯德哥爾摩，2021年8月27日/美通社/--領先的生物聚合公司BICO已經收購了專注於3D研究應用的美國公司Advanced BioMatrix Corp.(Advanced BioMatrix)的全部流通股。先進的BioMatrix產品組合包括膠原蛋白生物墨水、高純度細胞外基質蛋白、化學修飾的蛋白質和多糖以及其他試劑和細胞分析，銷售給研究機構、製藥和生物技術公司。該公司在試劑和生產用於3D生物打印的高質量膠原蛋白和膠原蛋白油墨方面擁有特別強大的地位。
BICO has acquired all outstanding shares in Advanced BioMatrix for a purchase price on a cash and debt-free basis of approximately USD 15 million, provided that the working capital upon completion of the transaction corresponds to the normalized working capital. The sellers may also receive a maximum additional earn out of USD 3 million in cash based on milestones over a three-year period.
BICO以現金和無債務的方式收購了Advanced BioMatrix的所有流通股，收購價約為1500萬美元，前提是交易完成後的營運資金與正常化營運資金相當。賣家還可以從以下項目獲得最高額外收入300萬美元以三年內的里程碑為基礎的現金。
Advanced BioMatrix was founded in 2008 and is based in San Diego, California, US. Combining the BICO Group and Advanced BioMatrix innovative offerings ensures a market-leading product portfolio in bioinks and reagents. Together the companies can also develop innovative application offerings to meet customers' future needs and demands, which also shows the strength of BICO's business model.
Advanced BioMatrix成立於2008年，總部設在美國加利福尼亞州聖地亞哥。將BICO集團和先進的BioMatrix創新產品相結合，確保了生物墨水和試劑領域的市場領先產品組合。兩家公司還可以共同開發創新的應用產品，以滿足客户未來的需求和要求，這也顯示了BICO商業模式的實力。
Advanced BioMatrix also has a broad portfolio of products for 3D applications including cell cultivation, cell assays and bioprinting, as well as a strong tradition of innovation with an ambitious R&D agenda. Advanced BioMatrix international customer base consists mainly of leading pharmaceutical companies and research institutions. The company's products are used, for example, in advanced research in the development of new drugs or 3D bioprinted tissue models. The company, like BICO, has a strong focus on IP.
Advanced BioMatrix還擁有廣泛的3D應用產品組合，包括細胞培養、細胞分析和生物打印，以及雄心勃勃的研發議程的強大創新傳統。先進的BioMatrix國際客户羣主要由領先的製藥公司和研究機構組成。例如，該公司的產品被用於新藥開發或3D生物打印組織模型的高級研究。與BICO一樣，該公司也非常專注於知識產權。
"Together with Advanced BioMatrix, we create the market's leading offering in bioinks and reagents. This means that we further strengthen our position in the area, and we can continue to develop innovative consumables that our customers benefit from throughout their customer journey. Combining technical expertise between the BICO Group and Advanced BioMatrix also enables faster development of innovative biomaterials for various bioprinting applications. Together, we will develop and offer innovative products that over time will lead to us being able to together solve the major health challenges we face." Erik Gatenholm, CEO, BICO.
"與先進的BioMatrix一起，我們創造了生物墨水和試劑市場的領先產品。這意味着我們進一步加強了我們在該領域的地位，我們可以繼續開發創新的消費品，讓我們的客户在整個客户之旅中受益。結合BICO集團和Advanced BioMatrix之間的技術專長，還可以更快地開發用於各種生物打印應用的創新生物材料。 我們將共同開發和提供創新產品，隨着時間的推移，這些產品將使我們能夠共同解決我們面臨的主要健康挑戰。埃裏克·加滕霍爾姆，BICO首席執行官。
"Advanced BioMatrix is ready for the next step in our growth and together with the BICO Group, we are ready to deliver the market's leading product portfolio of bioinks and reagents to our customers. We look forward to getting to know new colleagues, collaborators, and customers. We are excited to explore the potential that exists regarding synergies and sales opportunities within the Group". David Bagley, President, Advanced BioMatrix.
"Advanced BioMatrix已經為我們的下一步發展做好了準備，我們已經準備好與BICO集團一起，向我們的客户提供市場領先的生物墨水和試劑產品組合。我們期待着結識新的同事、合作者和客户。我們很高興能夠發掘集團內現有的協同效應和銷售機會David·巴格利，總裁，先進生物矩陣。
Advanced BioMatrix will, post-transaction, remain under current legal entity and management as a subsidiary of CELLINK Bioprinting and become part of the Bioprinting business area. Advanced BioMatrix will be integrated in the financial reporting as of August 2021. Advanced BioMatrix obtained approximately USD 3 million, with an adjusted EBITDA margin of around 50% in their latest fiscal year.
交易完成後，Advanced BioMatrix將作為CelLink Biopprint的子公司繼續處於當前的法律實體和管理之下，併成為Biopprint業務領域的一部分。截至2021年8月，Advanced BioMatrix將被整合到財務報告中。先進的生物矩陣獲得了大約300萬美元，調整後的EBITDA利潤率在最新財年約為50%。
For further information, please contact:
如需更多信息，請聯繫：
| Isabelle Ljunggren, Head of Communications | BICO Press office |
| 通聯部主管伊莎貝爾·永格倫(瑞典)電話：+46 70 830 0890電子郵件：[電子郵件受保護] | BICO Press辦公電話(美國)：公關經理Riley Munks：(650)863-6699公關經理Alyssa D‘Orazio：(617)634-9601電子郵件：[Email Protected] |
This information was submitted for publication, through the agency of the contact persons set out above, on August 27, 2021, at 8.30am (CEST).
這一信息是通過上述聯絡人的代理機構提交供公佈的。2021年8月27日，位於上午8時30分(中歐標準時間).
About BICO
關於BICO
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
BICO(前身為CelLink)成立於2016年，是全球領先的生物融合公司。通過將機器人、人工智能、計算機科學和3D生物打印等不同技術與生物相結合，我們使我們的客户能夠改善人們的健康和生活。
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
該公司專注於生物打印、多組學、細胞系開發和診斷等應用領域，開發和銷售創新技術，使生命科學領域的研究人員能夠以3D方式培養細胞，進行高通量藥物篩選，併為醫療、製藥和化粧品行業打印人體組織和器官。我們創造了健康的未來。
The Group's products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 2,950 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
該集團的產品受到2000多家實驗室的信任，其中包括所有排名前20位的製藥公司，目前正在超過65個國家和地區使用，並在2950多份出版物中被引用。BICO在納斯達克斯德哥爾摩上市，名稱為BICO。Www.bico.com
This information was brought to you by Cision http://news.cision.com
此信息由Cision http://news.cision.com為您提供
https://news.cision.com/bico-group-ab/r/bico-has-acquired-advanced-biomatrix--an-innovative-company-focused-on-3d-applications--to--together,c3404431
Https://news.cision.com/bico-group-ab/r/bico-has-acquired-advanced-biomatrix--an-innovative-company-focused-on-3d-applications--to--together，C3404431
The following files are available for download:
以下文件可供下載：
|
https://mb.cision.com/Main/14960/3404431/1459941.pdf |
210827-BICO has acquired Advanced BioMatrix |
|
Https://mb.cision.com/Main/14960/3404431/1459941.pdf |
210827-畢馬威收購了先進生物矩陣公司 |
SOURCE BICO Group AB
來源：BICO Group AB
譯文內容由第三人軟體翻譯。